Sagimet Biosciences Inc (NASDAQ: SGMT)’s stock price has dropped by -8.82 in relation to previous closing price of 2.38. Nevertheless, the company has seen a gain of 14.21% in its stock price over the last five trading days. globenewswire.com reported 2025-03-12 that Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB-3567, to be developed for the treatment of acne SAN MATEO, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2024, and provided recent corporate updates.
Is It Worth Investing in Sagimet Biosciences Inc (NASDAQ: SGMT) Right Now?
Company’s 36-month beta value is 2.63.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SGMT is 23.27M, and currently, short sellers hold a 17.00% ratio of that floaft. The average trading volume of SGMT on April 16, 2025 was 658.76K shares.
SGMT’s Market Performance
SGMT’s stock has seen a 14.21% increase for the week, with a -42.59% drop in the past month and a -47.77% fall in the past quarter. The volatility ratio for the week is 12.36%, and the volatility levels for the past 30 days are at 10.44% for Sagimet Biosciences Inc The simple moving average for the past 20 days is -26.91% for SGMT’s stock, with a -45.83% simple moving average for the past 200 days.
Analysts’ Opinion of SGMT
Many brokerage firms have already submitted their reports for SGMT stocks, with Oppenheimer repeating the rating for SGMT by listing it as a “Outperform.” The predicted price for SGMT in the upcoming period, according to Oppenheimer is $30 based on the research report published on December 06, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see SGMT reach a price target of $12. The rating they have provided for SGMT stocks is “Buy” according to the report published on November 12th, 2024.
Goldman gave a rating of “Neutral” to SGMT, setting the target price at $6 in the report published on June 28th of the previous year.
SGMT Trading at -39.57% from the 50-Day Moving Average
After a stumble in the market that brought SGMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.60% of loss for the given period.
Volatility was left at 10.44%, however, over the last 30 days, the volatility rate increased by 12.36%, as shares sank -43.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.43% lower at present.
During the last 5 trading sessions, SGMT rose by +14.21%, which changed the moving average for the period of 200-days by -47.20% in comparison to the 20-day moving average, which settled at $2.97. In addition, Sagimet Biosciences Inc saw -51.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGMT starting from Kemble George, who sale 23,625 shares at the price of $3.17 back on Jul 23 ’24. After this action, Kemble George now owns 118,693 shares of Sagimet Biosciences Inc, valued at $74,830 using the latest closing price.
Martins Eduardo Bruno, the Chief Medical Officer of Sagimet Biosciences Inc, sale 8,357 shares at $3.10 during a trade that took place back on Jul 19 ’24, which means that Martins Eduardo Bruno is holding 81,213 shares at $25,910 based on the most recent closing price.
Stock Fundamentals for SGMT
The total capital return value is set at -0.35. Equity return is now at value -36.92, with -35.46 for asset returns.
Based on Sagimet Biosciences Inc (SGMT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -544.04.
Currently, EBITDA for the company is -54.45 million with net debt to EBITDA at 1.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 34.23.
Conclusion
In a nutshell, Sagimet Biosciences Inc (SGMT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
